Shocker For MNCs: India Steps Closer To Granting Compulsory Licenses On Herceptin, Sprycel, Ixempra
This article was originally published in The Pink Sheet Daily
Executive Summary
Buckling under pressure from domestic drug makers and patient groups, India readies to grant compulsory licenses for three key cancer drugs.